Related Experiment Video
Updated: Aug 23, 2026
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
Expression of vascular endothelial growth factor (VEGF) in human osteosarcoma cells transfected with adeno-associated
Weiguo Xu1, Anmin Chen, Yibei Zhang
1Department of Orthopaedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Abstract:
The expression of protein vascular endothelial growth factor (VEGF) in osteosarcoma cells transfected with adeno-associated virus (rAAV)-antisense VEGF was studied to provide the foundation of osteosarcoma treatment through antivascularization. The rAAV-antisense VEGF at different doses (0, 20, 50, 100, 200, 240 microl) was transfected into osteosarcoma MG-63 cell. The cells and culture supernatants were collected before and after tansfection. The expression of VEGF protein was detected by using immunohistochemical staining (SP) and Western blot. SP and Western-blot tests revealed that the MG-63 Cells transfected with rAAV-antisense VEGF had less staining than those without transfection with rAAV-antisense VEGF, and the staining intensity was negatively correlated with the doses of genes. The corresponding A values of transfected genes with different doses of rAAV-antisense VEGF (0, 20, 50, 100, 200, 240 microl) were 86614 +/- 13776, 73245 +/- 15414, 61078 +/- 12124, 54657 +/- 10953, 39802 +/- 11308, 32014 +/- 15057 respectively, with the difference being significant (P<0.05). It was concluded that the expression of VEGF protein in MG-63 cells could be inhibited by rAAV-antisense VEGF.
Insights
Researchers inhibited vascular endothelial growth factor (VEGF) in osteosarcoma cells using adeno-associated virus (AAV) vectors. This study provides a foundation for antivascularization treatments in osteosarcoma.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Osteosarcoma is a primary bone malignancy.
- Vascular endothelial growth factor (VEGF) plays a crucial role in tumor angiogenesis and progression.
- Targeting VEGF offers a potential therapeutic strategy for osteosarcoma through antivascularization.
Purpose of the Study:
- To investigate the efficacy of adeno-associated virus (AAV)-mediated antisense VEGF gene therapy in inhibiting VEGF expression in osteosarcoma cells.
- To establish a foundation for developing antivascularization treatments for osteosarcoma.
Main Methods:
- Osteosarcoma MG-63 cells were transfected with varying doses of rAAV-antisense VEGF.
- VEGF protein expression was quantified using immunohistochemical staining (SP) and Western blot analysis.
- Cell culture supernatants and cells were collected pre- and post-transfection for analysis.
Main Results:
- Transfection with rAAV-antisense VEGF significantly reduced VEGF protein expression in MG-63 cells compared to controls.
- VEGF expression levels showed a negative correlation with the administered doses of rAAV-antisense VEGF.
- Statistical analysis confirmed the significance of the observed inhibition (P<0.05).
Conclusions:
- Adeno-associated virus (AAV)-mediated antisense VEGF gene therapy effectively inhibits VEGF protein expression in osteosarcoma cells.
- This approach holds promise for developing targeted antivascularization therapies for osteosarcoma.
- Further research into AAV-antisense VEGF therapy could lead to novel treatment strategies for osteosarcoma.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:10Mechanism of Angiogenesis